N-Halogenated Amine Compositions for Bronchopulmonary Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bronchopulmonary infections face challenges such as antimicrobial resistance, toxicity, and limited efficacy against viral and fungal infections, particularly in the deeper airways where traditional antiseptics are not well-tolerated due to irritative or toxic reactions.
Innovation Solution
The use of N-halogenated or N,N-dihalogenated amine compositions, including N-chlorotaurine and N,N-dichlorotaurine, which are administered via inhalation in combination with ammonium chloride, providing broad-spectrum antimicrobial activity without inducing resistance and are well-tolerated in the bronchopulmonary system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antiseptics are used to treat bronchopulmonary infections, then broad-spectrum antimicrobial activity is achieved, but significant irritative or toxic reactions occur and considerable systemic resorption takes place
Solution Approach 1:
The patent changes the chemical parameters of the antiseptic agents by using N-halogenated amines (specifically N-chlorotaurine and N,N-dichlorotaurine) instead of traditional antiseptics. These compounds have modified chemical properties that reduce toxicity and irritative effects while maintaining antimicrobial efficacy, thereby resolving the contradiction between broad-spectrum activity and harmful reactions
Solution Approach 2:
The patent employs short-acting N-halogenated amine compounds that are metabolized and eliminated quickly from the body. This approach allows for effective local antimicrobial action in the bronchopulmonary system while minimizing systemic accumulation and associated toxicity, addressing the contradiction between efficacy and harmful effects
2Reliability
If N-halogenated or N,N-dihalogenated amine compositions are administered via inhalation, then broad-spectrum antimicrobial activity is provided without inducing resistance, but the compositions must be carefully formulated to avoid toxicity
Solution Approach 1:
The patent optimizes the concentration parameters and chemical structure of the N-halogenated amine compositions to achieve effective antimicrobial activity while maintaining safety. By carefully controlling the formulation parameters, the compositions provide broad-spectrum coverage without inducing resistance and avoid toxic effects, resolving the contradiction between efficacy and safety
Solution Approach 2:
The patent uses ammonium chloride as an intermediary substance in combination with the N-halogenated amines. This combination enhances the antimicrobial activity and broadens the spectrum while maintaining safety profile, thereby achieving effective treatment without excessive toxicity or resistance development
3Ease of operation
If conventional antibiotics are used to treat bacterial infections, then targeted therapy is achieved, but antimicrobial resistance develops
Solution Approach 1:
The patent converts the non-specific action mechanism of traditional antiseptics into a benefit by using N-halogenated amines that work through unspecific oxidative mechanisms. This approach eliminates the development of antimicrobial resistance while providing broad-spectrum coverage against bacteria, fungi, and viruses, thereby transforming the potential harm of non-specificity into the advantage of resistance prevention
Solution Approach 2:
The patent employs N-halogenated amine compositions that provide universal antimicrobial activity against multiple types of pathogens including bacteria, fungi, and viruses. This multi-functional approach replaces targeted antibiotic therapy with a broad-spectrum agent that does not induce resistance, resolving the contradiction between targeted therapy and resistance development
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compositions effectively treat and prevent bronchopulmonary infections by maintaining effective oxygenation levels, reducing pulmonary artery pressure, and demonstrating broad-spectrum antimicrobial activity without systemic resorption or toxicity, making them suitable for patients with cystic fibrosis and immunocompromised individuals.
Implementation Method 1
The invention relates to antimicrobial, anti-infective, and disinfecting compositions for the treatment and prophylaxis of bronchopulmonary infections
Implementation Method 2
These compositions effectively treat and prevent bronchopulmonary infections by maintaining effective oxygenation levels
Implementation Method 3
reducing pulmonary artery pressure
Data Source
Figure 1~2
AI summary
Disclosed herein are methods and compositions for the treatment or prophylaxis, in a mammal, of bronchopulmonary infections, obstructive pulmonary disease, cystic fibrosis, and ventilator-associated infections. The methods and compositions include a therapeutically effective amount of one or more N-halogenated or N,N-dihalogenated amines, and their analogues, derivatives, or pharmaceutically acceptable salts and esters.